|
Apr 11
|
World risks ‘tepid Twenties’ as debt levels and inflation soar, warns IMF
|
|
Apr 11
|
AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
|
|
Apr 11
|
UPDATE 2-AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
|
|
Apr 11
|
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
|
|
Apr 11
|
Trending tickers: Darktrace, AstraZeneca, Persimmon, Bitcoin
|
|
Apr 11
|
CORRECTED-UPDATE 1-European shares dip ahead of ECB policy decision
|
|
Apr 11
|
AstraZeneca promises dividend rise ahead of vote on chief’s £18.7m pay deal
|
|
Apr 11
|
AstraZeneca announces dividend hike ahead of CEO pay vote
|
|
Apr 10
|
Major investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO
|
|
Apr 10
|
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
|
|
Apr 9
|
UK pharma companies told to make fewer drugs in draft net zero guidelines
|
|
Apr 8
|
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
|
|
Apr 8
|
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
|
|
Apr 7
|
10 Best Weight Loss Drug Stocks to Buy Now
|
|
Apr 6
|
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca PLC (LON:AZN)
|
|
Apr 6
|
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
|
|
Apr 6
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
|
|
Apr 5
|
15 Most Densely Populated Cities in Europe
|
|
Apr 5
|
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
|
|
Apr 5
|
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
|